Dendreon Prostate Vaccine Boosts Survival
Dendreon Corp. (DNDN) jolted the cancer community, and the stock market, on Apr. 14 with an announcement that a medical trial has shown that its experimental Provenge vaccine for prostate cancer can keep men alive longer than standard treatments. "The results were unambiguous," Dendreon CEO Mitchell Gold told BusinessWeek. The news raised the possibility that Provenge might become the first cancer vaccine approved for use in the U.S.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.